Sotera Health (SHC)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$18.90-0.68%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Intact: The reason to own it still holds.
Sotera Health grows revenue about 7% a year with steady profit. The company keeps earnings near $1.00 per share in 2026. It improved capital allocation by refinancing debt at lower costs. Leadership changes bring fresh strategy and stability.
Earnings growth may stall below $0.90 per share. Capital allocation might not improve as planned. Legal or market risks could hurt revenue growth below 5%.
The price is about 22% above our fair value near $14.70. Analysts expect 7% revenue growth, which aligns with company guidance. Our fair value is below the Street median, suggesting some valuation risk.
Breaks if: Capital costs rise or refinancing benefits reverse
Continue to refine and implement capital allocation strategies to optimize financial performance.
Breaks if: EPS falls below $0.81 per share in FY26
Focus on improving earnings performance to meet or exceed market expectations.
Breaks if: Leadership issues disrupt strategy or execution
Complete CEO transition and strengthen leadership team to support strategic growth and execution.
Leadership transition with new CEO was stated in 2 of last 2 quarters. The new CEO expressed confidence in the team and growth strategy. While no direct financial metrics tie to this priority, management has emphasized this transition as key to execution, showing initial delivery.
“CEO Alton Shader: 'Confident in delivering consistent and reliable growth.'”
“Company announced planned CEO transition in a separate release today”
Breaks if: Revenue falls below $1.16 billion in FY26
Focus on improving earnings performance to meet or exceed market expectations.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on consistent revenue and EBITDA growth. The current thesis state is stable, with management successfully raising guidance and demonstrating strong financial performance.
The market seems to have priced in a neutral valuation compared to peers, with an expectations gap indicating some room for improvement. However, the stock is viewed as somewhat stretched, reflecting a premium over its competitors.
Fundamentals are likely to continue showing robust earnings quality and strong financial performance, as management is on track with its growth goals. However, there is a moderate risk due to potential economic headwinds and the recent history of earnings surprises trending down.
The long-term thesis hinges on maintaining growth momentum in the healthcare sector, particularly if key industry players continue to perform well. Additionally, any negative shifts in guidance or economic indicators could impact investor confidence.
In summary, SHC is positioned well for the next few years, but it faces risks that could affect its trajectory. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this view. The company reported revenue of $321.37 million and adjusted EPS of $0.26. Management also raised full-year guidance for revenue and adjusted EBITDA. President Michael P. Rutz sold $2.83 million worth of shares. This sale may signal a change in management sentiment. James C. Neary resigned from the Board of Directors.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.